Skip to main
VRDN

Viridian Therapeutics (VRDN) Stock Forecast & Price Target

Viridian Therapeutics (VRDN) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 55%
Buy 45%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Viridian Therapeutics is positioned to be a successful company with its focused product candidates, differentiated approach to treating TED, and promising clinical data for its lead product veligrotug in active and chronic TED. The company's recent FDA approval for Lumvoa and positive early launch metrics indicate a strong potential for revenue growth in the future. With a diverse and inclusive workforce and a sustainable approach to healthcare, VRDN has the potential to achieve peak global sales of $600 million in 2029 and a fair value of $47 per share. However, risks include competition, regulatory hurdles, and the need for additional capital. Overall, our outlook is positive for VRDN given its promising portfolio and strong leadership.

Bears say

Viridian Therapeutics is facing multiple challenges that may negatively affect its stock performance. VRDN-001, its lead asset, is facing significant competition from AMGN's Tepezza, which has already captured a large portion of the thyroid eye disease market. Additionally, VRDN-003, Veligrotug's subcutaneous formulation, may not have a significant advantage over Tepezza, as Tepezza's market resiliency suggests that patient demand for TED treatment remains consistent. These factors, combined with potential regulatory, commercial, and pricing risks, may hinder VRDN's ability to achieve sustained growth and profitability.

Viridian Therapeutics (VRDN) has been analyzed by 11 analysts, with a consensus rating of Buy. 55% of analysts recommend a Strong Buy, 45% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Viridian Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Viridian Therapeutics (VRDN) Forecast

Analysts have given Viridian Therapeutics (VRDN) a Buy based on their latest research and market trends.

According to 11 analysts, Viridian Therapeutics (VRDN) has a Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $37.36, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $37.36, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Viridian Therapeutics (VRDN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.